

From: Drew Hutton

Sent: Monday, October 16, 2017 7:17 PM

To: Planning <Planning@a2gov.org>

Subject: REQUEST: Add to Oct. 17 Planning Commission Meeting Official Minutes

Esteemed Ann Arbor Planning Commission Members,

I am writing to kindly request that my enclosed correspondence please be shared with the Planning Commission and added to the official October 17th meeting record.

Specifically, I am writing to ask that the planning commission consider my proposal for an amendment to the *"DRAFT Medical Marijuana Zoning Ordinance For City Planning Commission 10/17/17 October 11, 2017."* In particular, Scientific Method Holdings, Inc., a Michigan Corporation, plans to seek city and state licensure through our two wholly-owned subsidiaries and operating companies, Scientific Method Research, LLC, and Scientific Method Technology, LLC, Michigan Limited Liability Companies, in operating under the Michigan MMFA as a co-located grower and processor. Our firms hope to lease shared-working space that is otherwise conformant to the proposed zoning draft within Research Park, in an RE-zoned parcel. Our firms business mission is the research and study of medical marijuana for the three accepted use cases medically, given the current scarcity of robust academic and medical research:

1. In developing products for use in assisting patients undergoing chemotherapy, specifically for treatment of nausea and pain.
2. In developing products for use in patients suffering from multiple-sclerosis.
3. In developing products for use in assisting those with extreme pain, given the addictive nature of opiod-derived products and the opiate epidemic our nation currently faces.

In particular, our firm aims to address the foremost problem internationally which must be solved with respect to the academic and medical study of cannabis products, and ensuing commercialization and regulatory oversight: the standardization and testing standards for Cannabis products.

It is accepted consensus that marijuana byproducts are known to operate through the endocannabinoid system of the brain. There are over 113 unique cannabinoids that have been observed in cannabis which are unique to the plant. In particular, THC and CBD have both received much press and awareness, however the remaining cannabinoid remain largely unstudied due to FDA hurdles that effectively block robust academic research. One leading researcher within this field, Ethan Russo, has published [academic evidence](#) that the volatile terpenes, responsible for the scent of all plants, have a carry-on effect with cannabinoids in the human brain. These organic compounds are notoriously unstable, which makes further research critical to the long-term viability of the medical marijuana industry. The relative cannabinoid and terpene profile of the harvested flower buds of the

cannabis plant vary according to a number of factors, including genotype (genetic composition), environment (growing methods) and phenotype (genetic expression).

Researching and understanding these factors is the intended business pursuit of Scientific Method Research, LLC, in reaching our parent company's aforementioned mission. In practice, this means developing [patentable intellectual property](#) through breeding and research, as well as the eventual [cloning](#) of genetically-stable and studied strains to large scale growers, to be purchased back for processing in the development of standardized medical-grade cannabis products.

Scientific Method Technology, LLC aims to develop the techniques and end-products created through from the harvested flower inputs in creating standardized, non-smoked, non-ingested, immediate onset products (i.e. vaporization, inhalers) for use in clinical settings.

LARA has recently issued an advisory regarding the co-location of [medical marijuana facilities](#) which would permit our two subsidiary companies, Scientific Method Research, LLC, and Scientific Method Technology, LLC to operate within the same facility if allowed by the City of Ann Arbor through its zoning ordinance. We strongly feel that our intended use is consistent with the overall zoning use regulation for the Research District overall:

5:10.14 RE Research District

(2) Permitted principle uses.

(a) Research, development, design, testing, technical training, and related activities for industrial, scientific, educational, and business enterprises;

(b) Laboratories for research, development and testing of, including, but not limited to, medical, optical, dental and pharmaceutical products; and

(e) Pilot manufacturing facilities for engineering, laboratory, scientific, electronic and research instruments and associated equipment.

Therefore, we ask that an amendment be made to allow for the co-location of processor and growing facilities within the RE district, as is allowed within the M-districts. It is imperative to both the financial feasibility of our efforts, and collaboration between academic and private enterprise in Ann Arbor, a city which not only has a long history of activism supporting the medical use of marijuana, but also the academic and medical infrastructure through the University of Michigan to emerge to the forefront of innovation of this multi-billion dollar global industry undergoing rapid growth and transformation. Failing to do so absence a well researched and understood rationale for the reasons threatens the some of the city's overall goals and initiatives of retaining the human capital produced through our University system and expanding the tax base to fund the operations and initiatives within Ann Arbor.

Thank you for your time and working regarding these important matters. Scientific Method Holdings, Inc. looks forward to working with Ann Arbor government and law enforcement through our operating subsidiaries within the regulatory framework that the City establishes and adopts.